A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Accumulating evidence supports the view that an imbalance of gut bacteria contributes to IBS, and that increasing the mass of beneficial species may reduce the numbers of pathogenic bacteria and help alleviate symptoms. METHODS: In this double-blind trial 400 adult patients with moderate-to-severe symptomatic diarrhea-predominant IBS (IBS-D) were randomized to treatment with the multi-strain probiotic Bio-Kult® (14 different bacterial strains) or placebo for 16 weeks. The change in severity and frequency of abdominal pain was the primary outcome measure. RESULTS: Probiotic treatment significantly improved the severity of abdominal pain in patients with IBS-D. A 69% reduction for probiotic versus 47% for placebo (p < 0.001) equates to a 145 point reduction on the IBS-severity scoring system (IBS-SSS). The proportion of patients who rated their symptoms as moderate-to-severe was reduced from 100% at baseline to 14% for the multi-strain probiotic at follow-up (month 5) versus 48% for placebo (p < 0.001). Also, the number of bowel motions per day from month 2 onwards was significantly reduced in the probiotic group compared with the placebo group (p < 0.05). In addition to relieving symptoms, the probiotic markedly improved all dimensions of quality of life in the 34-item IBS-Quality of Life (IBS-QoL) questionnaire. No serious adverse events were reported. CONCLUSIONS: The multi-strain probiotic was associated with significant improvement in symptoms in patients with IBS-D and was well-tolerated. These results suggest that probiotics confer a benefit in IBS-D patients which deserves further investigation. TRIAL REGISTRATION: [Clinicaltrials.gov NCT03251625 ; retrospectively registered on August 9, 2017].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155 · cited 1×
“The prevalence of IBS varies between geographic regions and populations, and is also dependent upon the diagnostic criteria used [4].”
The microbiome and innate immunity
Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016) · Nature · doi:10.1038/nature18847 · Cited by 2,012 · cited 1×
“It is undeniable that the gut microbiota has both direct and indirect effects on the immune system and inflammation [44, 45].”
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846 · cited 1×
“It is undeniable that the gut microbiota has both direct and indirect effects on the immune system and inflammation [44, 45].”
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“The IBS-SSS is a 5-item instrument used to measure severity of abdominal pain, frequency of abdominal pain (number of days with abdominal pain over the last 10 days), severity of abdominal distension, dissatisfaction with bowel habits, and interference with quality of life, each on a 100-point scale [35].”
Towards positive diagnosis of the irritable bowel.
Manning, A. P., Thompson, W. G., Heaton, K. W., & Morris, A. F. (1978) · BMJ · doi:10.1136/bmj.2.6138.653 · Cited by 1,374
Irritable Bowel Syndrome: A Clinical Review
Chey, W. D., Kurlander, J., & Eswaran, S. (2015) · JAMA · doi:10.1001/jama.2015.0954 · Cited by 1,081
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome
Saulnier, D. M., Riehle, K., Mistretta, T., Diaz, M., Mandal, D., Raza, S., Weidler, E. M., Qin, X., Coarfa, C., Milosavljevic, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.072 · Cited by 672 · cited 1×
“A decreased abundance of Bifidobacterium and Lactobacillus species [22], and an increase in Gammaproteobacteria species (a family comprised of numerous pathogens) [23] is frequently reported in IBS studies.”
Irritable bowel syndrome in the general population.
Jones, R., & Lydeard, S. (1992) · BMJ · doi:10.1136/bmj.304.6819.87 · Cited by 636 · cited 1×
“Despite being highly symptomatic and negatively impacting the individual’s quality of life (QoL), it has been noted that only about one-third of patients present to their general practitioners [9].”
Sperber, A. D., Dumitrascu, D., Fukudo, S., Gerson, C., Ghoshal, U. C., Gwee, K. A., Hungin, A. P. S., Kang, J.-Y., Minhu, C., Schmulson, M., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311240 · Cited by 554 · cited 1×
“Background Irritable bowel syndrome (IBS) is a common highly prevalent functional gastrointestinal (GI) disorder that places an enormous burden on resource-challenged healthcare systems [1, 2].”
Irritable bowel syndrome in general practice: prevalence, characteristics, and referral
Thompson, W. G., Heaton, K. W., Smyth, G. T., & Smyth, C. (2000) · Gut · doi:10.1136/gut.46.1.78 · Cited by 477
Psychometric scores and persistence of irritable bowel after infectious diarrhoea
Gwee, K. A., Read, N. W., Graham, J. C., McKendrick, M. W., Collins, S. M., Marshall, J. S., & Walters, S. J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90341-4 · Cited by 467
Review article: the economic impact of the irritable bowel syndrome
Canavan, C., West, J., & Card, T. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12938 · Cited by 458 · cited 1×
“Background Irritable bowel syndrome (IBS) is a common highly prevalent functional gastrointestinal (GI) disorder that places an enormous burden on resource-challenged healthcare systems [1, 2].”
Psychometric scores and persistence of irritable bowel after infectious diarrhoea
Ka, G., Graham, J. C., McKendrick, M. W., Collins, S. M., Marshall, J. S., Walters, S., & Read, N. W. (1996) · African journal of medical practice · Cited by 429
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424 · cited 1×
“The IBS-QoL questionnaire is a 34-item measure constructed specifically to assess QoL impairment due to IBS symptoms [36].”
Irritable bowel syndrome: A microbiome-gut-brain axis disorder?
Kennedy, P. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14105 · Cited by 331 · cited 1×
“A number of studies have shown a decrease in the microbial diversity of IBS patients compared to healthy controls [42], and specifically in relation to Bifidobacteria and Lactobacilli spp.”
Mättö, J., Maunuksela, L., Kajander, K., Palva, A., Korpela, R., Kassinen, A., & Saarela, M. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2004.08.009 · Cited by 301
Mechanisms and efficacy of dietary FODMAP restriction in IBS
Staudacher, H. M., Irving, P. M., Lomer, M. C. E., & Whelan, K. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.259 · Cited by 242
Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report
Drossman, D. A., Chang, L., Bellamy, N., Gallo-Torres, H. E., Lembo, A., Mearin, F., Norton, N. J., & Whorwell, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.201 · Cited by 226 · cited 1×
“According to Rome III criteria, abdominal pain or discomfort are hallmark determinants for the initial diagnosis of IBS and changes in bowel movements define different subtypes [16].”
Irritable bowel syndrome in developing countries – a disorder of civilization or colonization?
Gwee, K. ‐. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00627.x · Cited by 193
ZENG, J., LI, Y. ‐., ZUO, X. ‐., ZHEN, Y. ‐., YANG, J., & LIU, C. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03818.x · Cited by 189
Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0470-z · Cited by 181 · cited 1×
“The relatively high response in the placebo group has been previously reported in functional bowel disorder studies, which was shown to have a negative correlation with study duration [30].”
Asian consensus on irritable bowel syndrome
Gwee, K., Bak, Y., Ghoshal, U. C., Gonlachanvit, S., Lee, O. Y., Fock, K. M., Chua, A. S. B., Lu, C., Goh, K., Kositchaiwat, C., et al. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06353.x · Cited by 174
Sisson, G., Ayis, S., Sherwood, R. A., & Bjarnason, I. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12787 · Cited by 147
The Gut Microbiota and Irritable Bowel Syndrome: Friend or Foe?
Ghoshal, U. C., Shukla, R., Ghoshal, U., Gwee, K.-A., Ng, S. C., & Quigley, E. M. M. (2012) · International Journal of Inflammation · doi:10.1155/2012/151085 · Cited by 144
Masud, M. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02323-1 · Cited by 129
Staudacher, H. M., & Whelan, K. (2016) · Proceedings of the Nutrition Society · doi:10.1017/s0029665116000021 · Cited by 125 · cited 1×
“A decreased abundance of Bifidobacterium and Lactobacillus species [22], and an increase in Gammaproteobacteria species (a family comprised of numerous pathogens) [23] is frequently reported in IBS studies.”
SPIEGEL, B., BOLUS, R., HARRIS, L. A., LUCAK, S., NALIBOFF, B., ESRAILIAN, E., CHEY, W. D., LEMBO, A., KARSAN, H., TILLISCH, K., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04144.x · Cited by 112 · cited 2×
“Therefore, changes in the severity of abdominal pain are a reliable measure of treatment outcome and were assessed in this cohort using IBS-SSS questionnaire, which incorporates two pain-related items [29, 35, 37].”
Irritable bowel syndrome symptom severity improves equally with probiotic and placebo
Lyra, A., Hillilä, M., Huttunen, T., Männikkö, S., Taalikka, M., Tennilä, J., Tarpila, A., Lahtinen, S., Ouwehand, A. C., & Veijola, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10631 · Cited by 106 · cited 1×
“Furthermore, they are markedly greater than changes in IBS-SSS reported previously with a single strain probiotic after 12 weeks’ treatment (reduction of 50 points after 12 weeks) [38] and in multi-strain probiotic trial (reduction of 63 points after 12 weeks) [29].”
Roberts, L. M., McCahon, D., Holder, R., Wilson, S., & Hobbs, F. R. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-45 · Cited by 88
Bugs and irritable bowel syndrome: The good, the bad and the ugly
Ghoshal, U. C., Park, H., & Gwee, K. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06133.x · Cited by 88
McKenzie, Y. A., Thompson, J., Gulia, P., Lomer, M. C. E., & (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association) (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12386 · Cited by 80
Gwee, K.-A. (2010) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2010.16.1.30 · Cited by 79 · cited 1×
“Current evidence suggests that IBS patients have greater mucosal cellularity and other signs of increased inflammatory activity which might contribute to the development of IBS [12, 46].”
Perveen, I., Rahman, M. M., Saha, M., Rahman, M. M., & Hasan, M. Q. (2014) · Indian Journal of Gastroenterology · doi:10.1007/s12664-014-0447-1 · Cited by 67
Treatment of irritable bowel syndrome with probiotics: An etiopathogenic approach at last?
Bixquert Jiménez, M. (2009) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082009000800006 · Cited by 67 · cited 1×
“There is accumulating evidence showing that certain probiotics may be capable of significantly reducing abdominal pain, abdominal distension and flatulence while, at the same time, increasing health-related QoL in IBS patients [40].”
Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth
Lee, H.-R., & Pimentel, M. (2006) · Current Gastroenterology Reports · doi:10.1007/s11894-006-0051-3 · Cited by 61 · cited 1×
“Consequently, increasing the mass of beneficial species may help reduce the negative effects of pathogenic bacteria and help alleviate symptoms [28].”
Perveen, I., Hasan, M., Masud, M., Bhuiyan, M. R., & Rahman, M. (2009) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.56099 · Cited by 45
Probiotics in Irritable Bowel Syndrome: The Science and the Evidence
Quigley, E. M. M. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000348 · Cited by 41
An update on irritable bowel syndrome: from diagnosis to emerging therapies
Chang, J. Y., & Talley, N. J. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283414065 · Cited by 40
Bolino, C., & Berčík, P. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.07.005 · Cited by 37
Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome.
Kabir, M. A., Ishaque, S. M., Ali, M. S., Mahmuduzzaman, M., & Hasan, M. R. (2011) · PubMed · Cited by 31
Self-citationThe Future of Probiotics for Disorders of the Brain-Gut Axis
Quigley, E. M. M., & Shanahan, F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0897-4_19 · Cited by 20
Gut microbiota and functional diseases of the gastrointestinal tract
Imperatore, N., Tortora, R., Morisco, F., & Caporaso, N. (2017) · Minerva Gastroenterology · doi:10.23736/s1121-421x.16.02336-9 · Cited by 20 · cited 2×
“Current evidence suggests that IBS patients have greater mucosal cellularity and other signs of increased inflammatory activity which might contribute to the development of IBS [12, 46].”
Rahman, M. Z., Chowdhury, M. S., Rahman, M. A., Parveen, S., Barua, R., Ishaque, S. M., Ahmed, D. S., & Raihan, A. (2016) · Bangabandhu Sheikh Mujib Medical University Journal · doi:10.3329/bsmmuj.v6i1.29020 · Cited by 3 · cited 1×
“However, a follow-up study with a multi-strain probiotic yielded a beneficial outcome which was significant both clinically and statistically [33].”
Self-citation
Research works printed but not linked: 1
- Drossman DA Richter JE Talley NJ The functional gastrointestinal bowel disorders, pathophysiology and treatment: a multinational consensus 1994 Boston Little Brown
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209
Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review
Dale, H. F., Rasmussen, S. H., Asiller, Ö. Ö., & Lied, G. A. (2019) · Nutrients · doi:10.3390/nu11092048 · Cited by 166
AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
Preidis, G. A., Weizman, A. V., Kashyap, P. C., & Morgan, R. L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.060 · Cited by 127
Johnson, D., Thurairajasingam, S., Letchumanan, V., Chan, K., & Lee, L. (2021) · Nutrients · doi:10.3390/nu13051728 · Cited by 139
Metadata
- Authors
- Ishaque, S. M., Khosruzzaman, S. M., Ahmed, D. S., & Sah, M. P.
- Affiliations
- Bangladesh Medical University (BD)
- Corresponding author
- Ishaque, Shamsuddin M.
- Venue
- BMC Gastroenterology
- Published
- 2018-05-25
- Volume
- 18
- Issue
- 1
- Pages
- 71-71
- ISSN
- 1471-230X (ISSN-L)
- PMC
- PMC5970461
- OpenAlex
- W2807175397
- Cited by
- 109
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 19 · 2023: 22 · 2022: 7 · 2021: 16 · 2020: 16 · 2019: 7 · 2018: 1
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Gastroenterology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, multi-strain probiotics, diarrhea-predominant irritable bowel syndrome, abdominal pain, stool frequency, quality of life, gut microbiota, IBS symptom severity
- MeSH terms
- Gastrointestinal Microbiome, Adolescent, Adult, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Quality of Life, Severity of Illness Index, Abdominal Pain, Probiotics, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.